We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-5 of 5

IRS issues guidance on the dispute resolution process for the preliminary fee calculation of the 2011 fee imposed on manufacturers and importers of branded prescription drugs

  • Reed Smith LLP
  • -
  • USA
  • -
  • May 3 2011

On May 2, 2011, the Internal Revenue Service (the "IRS") issued Revenue Procedure 2011-24 (the "Revenue Procedure"), which establishes a dispute resolution process for the preliminary fee calculation for the 2011 fee imposed on certain manufacturers and importers of branded prescription drugs pursuant to the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"

IRS concludes attorney fees related to generic drug patent infringement lawsuits must be capitalized

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • January 24 2012

In a recent Chief Counsel Memorandum (“CCM”), the Internal Revenue Service (the “IRS”) concluded (contrary to an established industry custom) that attorney fees incurred for investigatory patent research and to defend actions for patent infringement in connection with the filing of abbreviated new drug applications (“ANDAs”) were not deductible and instead must be capitalized

Supreme Court on health reform and patent case budget transportation programs FCC reform cybersecurity

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • April 5 2012

With a two-week recess looming and the 2012 elections coming ever more into focus, Congress addressed a temporary fix on a critical deadline and set the stage for the budget debate, tax reform and other key considerations to be taken up over the Spring and Summer as it completed its most recent work period late last week

IRS capitalized legal fees incurred by pharmaceutical company

  • McDermott Will & Emery
  • -
  • USA
  • -
  • April 15 2013

In a recently released Field Attorney Advice, the Internal Revenue Service (IRS) Office of Chief Counsel concluded that a pharmaceutical company must

Noteworthy cases in the United States Supreme Court’s 2011 term

  • Larkin Hoffman
  • -
  • USA
  • -
  • September 21 2011

The first Monday in October represents the start of a new term for the United States Supreme Court

Current Search

Suggested Facets

Author

Firm Name

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy